Alice Blue Home
URL copied to clipboard

Trending News

Indoco Remedies shares gain on getting USFDA EIR for its API manufacturing facility

Indoco Remedies Limited received the USFDA Establishment Inspection Report for its Patalganga API manufacturing facility, confirming compliance with regulatory standards and enabling continued production for the US market.
Indoco Remedies gains after USFDA issues EIR for its API facility

Introduction

Leading pharmaceutical company received USFDA Establishment Inspection Report for its API manufacturing facility, confirming compliance with regulatory standards and enabling continued production of active pharmaceutical ingredients for the US market.

Alice Blue Image

Also Read: Astra Microwave gains on winning ₹171.38 Cr order for IMD radar

Share price movement of Indoco Remedies

On December 12, 2025, Indoco Remedies Ltd opened at ₹240.00, up 0.25% from its previous close of ₹239.40. The stock reached a high of ₹251.05 (4.59%) and a low of ₹239.25. By 3:41 PM, it traded at ₹240.75, a 0.56% increase, with a market cap of ₹2,220.87 crore.

Indoco Receives USFDA Approval for Facility

Indoco Remedies Limited announced it received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Patalganga. The inspection took place from September 15 to 19, 2025.

The facility successfully met all regulatory requirements. The EIR confirms compliance with USFDA standards. Indoco can continue manufacturing Active Pharmaceutical Ingredients for the US market without restrictions.

Stock performance of Indoco Remedies for Period of 1 week, 6 months, and 1 year

Indoco Remedies Ltd delivered a -4.87% return over the past week, it declined by 14.7% in the past six months. The stock fell 28.6% over the past year.

Alice Blue Image

Also Read: Tembo Global Industries secures ₹700 crore pipeline for large industrial projects

Shareholding pattern of Indoco Remedies

ParticularsSep 2025Jun 2025Mar 2025
Promoter58.90%58.90%58.90%
FII1.30%1.20%1.20%
DII18.20%19.00%18.80%
Public22%21%21%

About Indoco Remedies

Indoco Remedies Ltd (NSE: INDOCO) is a research-driven pharmaceutical company with 11 manufacturing facilities, a global presence, diverse therapeutic products, strong R&D, and over 6,000 employees supporting domestic and international markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Indoco Remedies Ltd share price going up today?

A: Indoco Remedies Ltd announced it received the USFDA EIR for its API manufacturing facility at Patalganga.

Q: What does Indoco Remedies Ltd specialize in?

A: Indoco Remedies Ltd specializes in research-driven pharmaceutical products, including APIs, FDFs, and diverse therapeutic formulations for domestic and international markets.

Q: What is the market capitalization of Indoco Remedies Ltd?

A: The market capitalization of Indoco Remedies Ltd stands at ₹2,220.87 crore as of December 12, 2025.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News
गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत
Global Market

गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत

मेटा डिस्क्रिप्शन: गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12 के संकेतों से भारतीय बाजारों में सकारात्मक शुरुआत की उम्मीद है। कच्चे

*T&C apply